Zealand Pharma (ZEAL) Collaboration summary

Opening remarks and agenda

• Announced a global exclusive collaboration and license agreement between Zealand Pharma and Roche to co-develop and co-commercialize petrelintide for overweight and obesity, with a conference call to discuss the partnership, strategic rationale, product overview, financials, and Q&A.

Objectives of the partnership

• Aim to establish petrelintide as a foundational therapy for weight management and expand into related indications, redefining the standard of care for overweight and obesity with a leading amylin-based franchise.

• Shared vision to address high unmet medical needs in obesity, both as monotherapy and in combination therapies.

Partner introductions and roles

• Zealand Pharma: biotech company focused on peptide-based medicines, represented by key executives, will co-develop and co-commercialize petrelintide and pay Roche for CT-388's contribution.

• Roche: brings global R&D, manufacturing, and commercial capabilities, will contribute CT-388, lead commercial manufacturing and supply, and hold exclusive commercialization rights outside the US and Europe.